Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Phase 1

Recruiting

Conditions: Hematologic Neoplasms

Interventions: Procedure: donor lymphocyte infusion
Drug: Cyclophosphamide
Drug: Busulfan
Drug: Mycophenolate mofetil
Drug: Fludarabine
Drug: Sirolimus

First Posted Date: 2022-04-14

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 430

Registration Number: NCT05327023

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Biological: fhB7H3.CAR-Ts
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-04-12

Last Posted Date: 2022-04-12

Lead Sponsor: The Affiliated Hospital of Xuzhou Medical University

Target Recruit Count: 15

Registration Number: NCT05323201

Locations: 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions: Drug: Orelabrutinib
Drug: Obinutuzumab
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-04-12

Last Posted Date: 2022-04-19

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 25

Registration Number: NCT05322733

Locations: 🇨🇳
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin, Jiangsu, China

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Phase 1

Withdrawn

Conditions: Recurrent Acute Myeloid Leukemia
Recurrent Mixed Phenotype Acute Leukemia
Refractory T Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Recurrent T Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
Refractory Mixed Phenotype Acute Leukemia

Interventions: Drug: Anti-CD123 ADC IMGN632
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Drug: Cytarabine
Drug: Fludarabine Phosphate
Drug: Hydrocortisone Sodium Succinate
Drug: Methotrexate
Drug: Prednisolone

First Posted Date: 2022-04-11

Last Posted Date: 2023-09-01

Lead Sponsor: Children's Oncology Group

Registration Number: NCT05320380

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia Refractory
Acute Myeloid Leukemia, in Relapse

Interventions: Drug: Venetoclax
Drug: Azacitadine
Drug: Vorinostat
Drug: Cytarabine
Drug: Fludarabine
Drug: Filgrastim

First Posted Date: 2022-04-07

Last Posted Date: 2024-11-26

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 40

Registration Number: NCT05317403

Locations: 🇺🇸
Children's Wisconsin, Milwaukee, Wisconsin, United States

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Phase 2

Not yet recruiting

Conditions: Neuroblastoma

Interventions: Drug: Anti Thymocyte Globulin
Drug: Fludarabine
Drug: Cyclophosphamide injection
Drug: Topotecan
Drug: Melphalan
Drug: Thiotepa
Drug: Busulfan
Drug: Cyclosporine
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Methotrexate

First Posted Date: 2022-03-31

Last Posted Date: 2022-07-01

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 64

Registration Number: NCT05303727

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

Phase 2

Withdrawn

Conditions: Stem Cell Transplantation

Interventions: Drug: Fludarabine
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Cyclophosphamide (Cy)
Drug: Bortezomib
Drug: Rituximab
Drug: Mycophenolate mofetil (MMF)
Drug: Busulfan
Drug: Rabbit ATG
Drug: Tacrolimus (or cyclosporine)

First Posted Date: 2022-03-24

Last Posted Date: 2023-09-21

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05293509

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Bortezomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Cilta-cel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2022-02-25

Last Posted Date: 2024-11-14

Lead Sponsor: Stichting European Myeloma Network

Target Recruit Count: 750

Registration Number: NCT05257083

Locations: 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
UC San Diego Health Moores Cancer Center, San Diego, California, United States

and more 122 locations

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Terminated

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma

Interventions: Drug: BMS-986403
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-02-17

Last Posted Date: 2023-07-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5

Registration Number: NCT05244070

Locations: 🇺🇸
Local Institution - 0026, Hackensack, New Jersey, United States
🇺🇸
Local Institution - 0007, Boston, Massachusetts, United States
🇺🇸
Local Institution - 0005, Birmingham, Alabama, United States

and more 5 locations

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Phase 1

Recruiting

Conditions: Platinum-Resistant Ovarian Carcinoma

Interventions: Biological: Chimeric Antigen Receptor T-cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2022-02-04

Last Posted Date: 2024-05-23

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 33

Registration Number: NCT05225363

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy